GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Esperion Therapeutics Inc (STU:0ET) » Definitions » E10

Esperion Therapeutics (STU:0ET) E10 : €-4.82 (As of Sep. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Esperion Therapeutics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Esperion Therapeutics's adjusted earnings per share data for the three months ended in Sep. 2024 was €-0.135. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-4.82 for the trailing ten years ended in Sep. 2024.

During the past 3 years, the average E10 Growth Rate was 8.30% per year. During the past 5 years, the average E10 Growth Rate was 7.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Esperion Therapeutics was 16.90% per year. The lowest was 5.40% per year. And the median was 9.45% per year.

As of today (2025-03-02), Esperion Therapeutics's current stock price is €1.603. Esperion Therapeutics's E10 for the quarter that ended in Sep. 2024 was €-4.82. Esperion Therapeutics's Shiller PE Ratio of today is .


Esperion Therapeutics E10 Historical Data

The historical data trend for Esperion Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Esperion Therapeutics E10 Chart

Esperion Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.62 -6.05 -5.59 -4.69 -5.00

Esperion Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.07 -5.00 -4.85 -5.21 -4.82

Competitive Comparison of Esperion Therapeutics's E10

For the Drug Manufacturers - Specialty & Generic subindustry, Esperion Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Esperion Therapeutics's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Esperion Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Esperion Therapeutics's Shiller PE Ratio falls into.



Esperion Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Esperion Therapeutics's adjusted earnings per share data for the three months ended in Sep. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-0.135/133.0289*133.0289
=-0.135

Current CPI (Sep. 2024) = 133.0289.

Esperion Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201412 -0.397 99.070 -0.533
201503 -0.517 99.621 -0.690
201506 -0.490 100.684 -0.647
201509 -0.508 100.392 -0.673
201512 -0.532 99.792 -0.709
201603 -0.584 100.470 -0.773
201606 -0.552 101.688 -0.722
201609 -0.686 101.861 -0.896
201612 -1.223 101.863 -1.597
201703 -1.683 102.862 -2.177
201706 -1.709 103.349 -2.200
201709 -1.561 104.136 -1.994
201712 -1.217 104.011 -1.557
201803 -1.403 105.290 -1.773
201806 -1.464 106.317 -1.832
201809 -1.594 106.507 -1.991
201812 -1.969 105.998 -2.471
201903 2.717 107.251 3.370
201906 -1.779 108.070 -2.190
201909 -2.288 108.329 -2.810
201912 -2.034 108.420 -2.496
202003 -2.570 108.902 -3.139
202006 3.836 108.767 4.692
202009 -2.606 109.815 -3.157
202012 -3.198 109.897 -3.871
202103 -2.940 111.754 -3.500
202106 -1.386 114.631 -1.608
202109 -2.227 115.734 -2.560
202112 -1.566 117.630 -1.771
202203 -0.844 121.301 -0.926
202206 -0.993 125.017 -1.057
202209 -0.818 125.227 -0.869
202212 -0.717 125.222 -0.762
202303 -0.738 127.348 -0.771
202306 -0.425 128.729 -0.439
202309 -0.347 129.860 -0.355
202312 -0.458 129.419 -0.471
202403 0.313 131.776 0.316
202406 -0.307 132.554 -0.308
202409 -0.135 133.029 -0.135

Add all the adjusted EPS together and divide 10 will get our e10.


Esperion Therapeutics  (STU:0ET) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Esperion Therapeutics E10 Related Terms

Thank you for viewing the detailed overview of Esperion Therapeutics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Esperion Therapeutics Business Description

Traded in Other Exchanges
Address
3891 Ranchero Drive, Suite 150, Ann Arbor, MI, USA, 48108
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

Esperion Therapeutics Headlines

No Headlines